Minimed Can Complete Additional Glucose Monitor Studies In Six Weeks
This article was originally published in The Gray Sheet
Executive SummaryMinimed's continuous glucose monitoring system could be on the market in six weeks, pending completion of two short premarket studies deemed conditions of a unanimous (10-0) approvable decision reached by FDA's Clinical Chemistry and Clinical Toxicology Devices Panel on Feb 26.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.